Chimeric TherapeuticsCHMMF -96.67%13 EBIT per Share is $-0.52 as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,179 Biotechnology companies, Chimeric Therapeutics ranks better than 76.84% on this metric.
Chimeric Therapeutics's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.52.
During the past 3 years, the average EBIT per Share Growth Rate was 37.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Chimeric Therapeutics's EBIT per Share or its related term are showing as below:
CHMMF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 28.6 Med: 33 Max: 37.4
Current: 37.4
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Chimeric Therapeutics was 37.40% per year. The lowest was 28.60% per year. And the median was 33.00% per year.
CHMMF's 3-Year EBIT Growth Rate is ranked better than 76.84% of 1179
companies
in the Biotechnology industry
Industry Median: 15.6
vs CHMMF: 37.40
Chimeric Therapeutics (OTCPK:CHMMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Chimeric Therapeutics EBIT per Share Related Terms
Chimeric Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics (CHMMF) has a EBIT per Share of $-0.52 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #273 out of 1179 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Chimeric Therapeutics' EBIT per Share too high?
Chimeric Therapeutics' current EBIT per Share is $-0.52. Based on the distribution chart, Chimeric Therapeutics ranks #273 out of 1179 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #273 out of 1179 companies for EBIT per Share. This places Chimeric Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,179 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current EBIT per Share is $-0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current EBIT per Share of $-0.52. The current EBIT per Share is $-0.52. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current EBIT per Share is $-0.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
